Enliven Therapeutics, Inc. SEC filings ELVN
Enliven Therapeutics, Inc. has 798 filings in SEC EDGAR's recent list, going back to Apr 21, 2016. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 27, 2026 | — |
| DEF 14A | Proxy statement | Apr 27, 2026 | Jun 9, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 15, 2026 | Jun 9, 2026 |
| DEFA14A | Additional proxy material | Apr 28, 2025 | — |
| DEF 14A | Proxy statement | Apr 28, 2025 | Jun 24, 2025 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 18, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 15, 2024 | Jun 18, 2024 |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 23, 2023 |
| DEFA14A | Additional proxy material | Oct 19, 2022 | — |
| DEFM14A | Filing | Oct 7, 2022 | — |
| PREM14A | Filing | Sep 23, 2022 | Sep 23, 2022 |
| DEFA14A | Additional proxy material | Sep 7, 2022 | — |
| DEFA14A | Additional proxy material | Apr 22, 2022 | — |
| DEF 14A | Proxy statement | Apr 22, 2022 | Jun 2, 2022 |
| DEFA14A | Additional proxy material | May 18, 2021 | — |
| DEF 14A | Proxy statement | May 18, 2021 | Jun 29, 2021 |
Showing 18 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ELVN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Burlingame, CA
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1672619
- Former names
- IMARA Inc. (until Feb 23, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.